Caitong International Asset Management Co. Ltd Makes New Investment in HCA Healthcare, Inc. $HCA

Caitong International Asset Management Co. Ltd acquired a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 523 shares of the company’s stock, valued at approximately $200,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HCA. Price T Rowe Associates Inc. MD raised its position in shares of HCA Healthcare by 83.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after buying an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in HCA Healthcare by 49.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after purchasing an additional 587,036 shares during the period. Nuveen LLC acquired a new position in shares of HCA Healthcare during the 1st quarter valued at $569,217,000. Pacer Advisors Inc. lifted its holdings in shares of HCA Healthcare by 6,237.9% in the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after buying an additional 1,329,618 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in HCA Healthcare by 6.8% in the 2nd quarter. Nordea Investment Management AB now owns 927,781 shares of the company’s stock valued at $350,404,000 after acquiring an additional 59,163 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company’s stock.

HCA Healthcare Stock Down 0.3%

Shares of NYSE HCA opened at $440.07 on Friday. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $447.09. The firm has a market capitalization of $102.97 billion, a P/E ratio of 18.50, a P/E/G ratio of 1.39 and a beta of 1.40. The stock’s 50-day simple moving average is $413.82 and its two-hundred day simple moving average is $380.88.

HCA Healthcare (NYSE:HCA) last announced its earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The business had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same period in the previous year, the business posted $5.50 earnings per share. HCA Healthcare’s revenue for the quarter was up 6.4% on a year-over-year basis. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

Analyst Ratings Changes

HCA has been the subject of a number of analyst reports. Robert W. Baird upped their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the company a “neutral” rating in a research note on Thursday, August 14th. Weiss Ratings reissued a “buy (b-)” rating on shares of HCA Healthcare in a research report on Wednesday, October 8th. Mizuho boosted their price objective on HCA Healthcare from $425.00 to $475.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Wall Street Zen upgraded shares of HCA Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Finally, UBS Group raised their price target on shares of HCA Healthcare from $438.00 to $495.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $437.19.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.